Legend Biotech (9LB) AI Stock Analysis

1 Followers

Legend Biotech

(Frankfurt:9LB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

CARVYKTI Commercial GrowthStrong CARVYKTI growth across U.S. and international markets indicates expanding product adoption and commercial reach. Rising earlier-line use, new country launches, and broader treatment access can support sustained revenue growth and improve operating leverage over the next several quarters.

Negative Factors

Persistent Cash BurnDespite improving earnings, Legend remains cash-flow negative, showing that the business is not yet consistently self-funding. Continued operating and development outflows could require use of liquidity or external financing, limiting flexibility if profitability progress slows.

Legend Biotech (9LB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.61B
Dividend Yield: ―
Average Volume (3M): 244
Price to Earnings (P/E): -1954.0
Beta (1Y): 0.60
Revenue Growth: 42.96%
EPS Growth: 99.21%
Country: Germany
Employees: 3,200
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Legend Biotech Business Overview & Revenue Model

Company Description

Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe....

Legend Biotech Earnings Call Summary

Earnings Call Date:Nov 10, 2026(Q3-2026)|% Change Since:-13.55%|Next Earnings Date:Mar 16, 2027

Earnings Call SentimentPositive

The call was strongly positive overall. CARVYKTI delivered 36% year-over-year net trade sales growth, international growth was 86%, earlier-line adoption continued to expand, long-term clinical data remained favorable, LB2501 showed encouraging early activity, and profitability and operating leverage improved materially. The main challenges were slower-than-anticipated earlier-line growth in the U.S., international launch delays, increasing competition from bispecifics and other CAR-T therapies, and event-driven timing for later-stage clinical readouts.

Positive Updates

CARVYKTI Net Trade Sales Growth

Third-quarter CARVYKTI net trade sales increased approximately 36% year-over-year to $710 million, driven by continued adoption in earlier-line settings in the U.S. and new country launches.

Negative Updates

Slower U.S. Earlier-Line Share Growth

Management said earlier-line share growth in the U.S. has been slower than previously anticipated, and described slower earlier-line share growth in the U.S. as one reason the current 2027 net trade sales consensus is at the higher end of the scenarios currently anticipated.

Company Guidance

Management expects to achieve company-wide profitability for full year 2026 on an adjusted net income basis, with fourth quarter gross margin on net product sales in the high 50% range; it is still expecting substantial year-over-year growth on a global basis, double-digit growth year-over-year for CARVYKTI in '27, and a $5 billion-plus potential for the product, while noting that Q4 sales consensus and current net trade sales consensus for 2027 would be at the higher end of the scenarios currently anticipated due to launch delays in the OUS markets and slower earlier line share growth in the U.S. than initially anticipated. The soonest readout for CARTITUDE-5 would be in 2027, with CARTITUDE-6 beyond that, and Phase Ia for LB2501 is intended to potentially transition quickly into Phase Ib, followed by Phase II in appropriately selected patient populations.

Legend Biotech Risk Analysis

Legend Biotech disclosed 117 risk factors in its most recent earnings report. Legend Biotech reported the most risks in the "Legal & Regulatory" category.

Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

3 New Risks

1.Disruptions at the FDA, the SEC and other government agencies and regulatory authorities caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.Q4, 2025

2.We face pricing and reimbursement risks related to ongoing and proposed U.S. government policies intended to lower prescription drug prices, including initiatives that tie U.S. drug pricing to prices paid in other developed nations. These policies could materially and adversely affect our revenue, profitability, and the commercial viability of our products.Q4, 2025

3.Our reputation is key to our business success. Negative publicity and allegations involving us, our affiliates, directors, officers or employees may adversely affect our reputation, business and growth prospects.Q4, 2025

Legend Biotech Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:9LB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ADPT	64Neutral	$4.75B	-66.53	-37.40%	―	17.91%	16.01%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IOVA	51Neutral	$3.74B	-15.26	-29.71%	―	51.31%	56.78%
PGEN	46Neutral	$1.62B	69.11	57.93%	―	2387.61%	―
IMTX	44Neutral	$960.66M	-3.61	-52.19%	―	-44.50%	-80.18%
SANA	44Neutral	$728.11M	-4.32	-97.08%	―	―	45.15%

* Healthcare Sector Average

Performance Comparison

DE:9LB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:9LB	Legend Biotech Corporation	18.50	-8.30	-30.97%
PGEN	Precigen, Inc.	4.72	0.86	22.28%
IOVA	Iovance Biotherapeutics	8.09	5.68	235.68%
ADPT	Adaptive Biotechnologies	29.94	15.80	111.74%
IMTX	Immatics N.V.	6.69	-3.29	-32.97%
SANA	Sana Biotechnology, Inc.	2.29	-1.37	-37.43%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Legend Biotech AI Stock Analysis